PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher

被引：7

作者：

Allen, Pamela Blair

Gordon, Leo I.

机构：

[1] Northwestern Univ, Dept Med, Feinberg Sch Med, Lymphoma Program,Div Hematol Oncol, Chicago, IL 60611 USA

[2] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

来源：

EXPERT REVIEW OF HEMATOLOGY | 2016年 / 9卷 / 10期

关键词：

Pembrolizumab; nivolumab; PD-1; PD-L1; PD-L2; checkpoint inhibitor(s); classical Hodgkin's lymphoma (HL); STEM-CELL-TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; BRENTUXIMAB VEDOTIN; OPEN-LABEL; PHASE-II; PROGNOSTIC-FACTORS; T-CELLS; NIVOLUMAB; DISEASE; SAFETY;

D O I：

10.1080/17474086.2016.1235970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Classical Hodgkin's Lymphoma (cHL) is characterized by genetic reliance on the PD-1 pathway. Rapid accumulation of data describing the role and efficacy of PD-1 and its blockade warrants a focused review.Areas covered: In this article, we will review the unique biologic features that predispose cHL to PD-1 inhibition, current data regarding the safety and efficacy of PD-1 inhibitors in the treatment of cHL, biomarkers of immune response, ongoing clinical trials with PD-1 inhibitors, as well as areas of uncertainty.Expert commentary: The biologic and genetic underpinnings of cHL make it unique among all malignancies in its exquisite sensitivity to PD-1 inhibition. High response rates to single agent PD-1 inhibitors in early phase clinical trials serve as further proof of concept. These data strongly support continued clinical investigation of the evolving role of PD-1 inhibition in classical Hodgkin's lymphoma, including the optimal sequence, setting, and combination to best exploit the immunologic properties of this disease.

引用

页码：939 / 949

页数：11

共 71 条

[11] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[12] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[13] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[14] Managing relapsed and refractory Hodgkin lymphoma [J].

Brice, Pauline .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (01) :3-13

[15] Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial [J].

Carde, Patrice ;

Karrasch, Matthias ;

Fortpied, Catherine ;

Brice, Pauline ;

Khaled, Hussein ;

Casasnovas, Olivier ;

Caillot, Denis ;

Gaillard, Isabelle ;

Bologna, Serge ;

Ferme, Christophe ;

Lugtenburg, Pieternella Johanna ;

Morschhauser, Frank ;

Aurer, Igor ;

Coiffier, Bertrand ;

Meyer, Ralph ;

Seftel, Matthew ;

Wolf, Max ;

Glimelius, Bengt ;

Sureda, Anna ;

Mounier, Nicolas .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (17) :2028-+

[16] RNA fingerprints provide direct evidence for the inhibitory role of TGFβ and PD-1 on CD4+ T cells in Hodgkin lymphoma [J].

Chemnitz, Jens M. ;

Eggle, Daniela ;

Driesen, Julia ;

Classen, Sabine ;

Riley, James L. ;

Debey-Pascher, Svenja ;

Beyer, Marc ;

Popov, Alexey ;

Zander, Thomas ;

Schultze, Joachim L. .

BLOOD, 2007, 110 (09) :3226-3233

[17]

Cheson BD, 2016, BLOOD, V29, P2016

[18] Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial [J].

Eich, Hans Theodor ;

Diehl, Volker ;

Goergen, Helen ;

Pabst, Thomas ;

Markova, Jana ;

Debus, Juergen ;

Ho, Anthony ;

Doerken, Bernd ;

Rank, Andreas ;

Grosu, Anca-Ligia ;

Wiegel, Thomas ;

Karstens, Johann Hinrich ;

Greil, Richard ;

Willich, Normann ;

Schmidberger, Heinz ;

Doehner, Hartmut ;

Borchmann, Peter ;

Mueller-Hermelink, Hans-Konrad ;

Mueller, Rolf-Peter ;

Engert, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4199-4206

[19] Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial [J].

Engert, Andreas ;

Haverkamp, Heinz ;

Kobe, Carsten ;

Markova, Jana ;

Renner, Christoph ;

Ho, Antony ;

Zijlstra, Josee ;

Kral, Zdenek ;

Fuchs, Michael ;

Hallek, Michael ;

Kanz, Lothar ;

Doehner, Hartmut ;

Doerken, Bernd ;

Engel, Nicole ;

Topp, Max ;

Klutmann, Susanne ;

Amthauer, Holger ;

Bockisch, Andreas ;

Kluge, Regine ;

Kratochwil, Clemens ;

Schober, Otmar ;

Greil, Richard ;

Andreesen, Reinhard ;

Kneba, Michael ;

Pfreundschuh, Michael ;

Stein, Harald ;

Eich, Hans Theodor ;

Mueller, Rolf-Peter ;

Dietlein, Markus ;

Borchmann, Peter ;

Diehl, Volker .

LANCET, 2012, 379 (9828) :1791-1799

[20] Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma [J].

Engert, Andreas ;

Pluetschow, Annette ;

Eich, Hans Theodor ;

Lohri, Andreas ;

Doerken, Bernd ;

Borchmann, Peter ;

Berger, Bernhard ;

Greil, Richard ;

Willborn, Kay C. ;

Wilhelm, Martin ;

Debus, Juergen ;

Eble, Michael J. ;

Soekler, Martin ;

Ho, Antony ;

Rank, Andreas ;

Ganser, Arnold ;

Truemper, Lorenz ;

Bokemeyer, Carsten ;

Kirchner, Hartmut ;

Schubert, Joerg ;

Kral, Zdenek ;

Fuchs, Michael ;

Mueller-Hermelink, Hans-Konrad ;

Mueller, Rolf-Peter ;

Diehl, Volker .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (07) :640-652

← 1 2 3 4 5 6 7 8 →